相关实验视频

Updated: Aug 7, 2026

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

多糖类作为减少剂:自组合复合纳米颗粒用于综合性糖尿病伤口治疗

Xiaofei Huang¹, Lihua Shi¹, Yin Lin¹

¹Shandong Key Laboratory of Proteins and Peptides Pharmaceutical Engineering, Shandong Universities Key Laboratory of Biological Medicine, School of Life Science and Technology, Weifang Medical University, Weifang, Shandong, 261053, People's Republic of China.

International journal of nanomedicine

|November 1, 2023

概括

这项研究开发了来自Pycnoporus sanguineus的基于多糖的新型复合颗粒 (PCP),用于治疗糖尿病足 (DFU). PCP有效降低了氧化应激和细菌感染,促进了伤口愈合.

科学领域:

生物材料科学生物材料科学
伤口治愈研究研究伤口治愈研究
纳米医学是一种纳米医学.

背景情况:

糖尿病足 (DFU) 是一种严重的糖尿病并发症,通常受到高反应性氧物种 (ROS) 和细菌感染的阻碍.
目前的DFU治疗方法在同时解决氧化应激和微生物威胁方面面临挑战.

研究的目的:

从Pycnoporus sanguineus合成基于多糖的新型复合颗粒 (PCP),用于DFU治疗.
评估PCP的抗氧化,抗微生物和伤口愈合能力在体外和体内.
研究PCP在降低ROS水平和对抗糖尿病伤口中的细菌感染方面的潜力.

主要方法:

来自P. sanguineus的多糖被用于用银离子制造PCP.
使用包括UV-Vis,TEM,FTIR,XRD和DLS在内的技术来表征PCP.
实验室,细胞和糖尿病的小鼠模型被用于评估抗氧化剂,抗菌素和伤口愈合效应.

主要成果:

合成的PCP表现出球形形态 (平均尺寸为57.29±22.41nm),具有联合抗氧化和抗微生物特性.
PCP显著减少了54%的细胞ROS,并且在低度下表现出强大的抗菌活性.
在体内研究表明,PCP增强了抗氧化酶 (SOD,CAT),加速了DFU愈合,并降低了感染风险.

结论:

开发的PCP代表了DFU治疗的有希望的,全面的治疗策略.
结合抗氧化和抗微生物功能,PCP有效促进伤口愈合并减轻患者的痛苦.
这项研究突出了糖尿病综合性伤口管理的新方法,并扩大了P. sanguineus多糖的应用.

关键词:

皮克诺波鲁斯血流性血流性它是一种抗菌药物,具有抗菌作用.抗氧化剂是一种抗氧化剂.伤害伤害伤害伤害伤害伤害伤害伤害伤害聚糖是一种多糖.

更多相关视频

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

相关概念视频

Oral Hypoglycemic Agents: Sulfonylureas

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...